Evidence map›Paper›PMID 40500427›Full record

ArticleMedical oncology (Northwood, London, England)2025

Evaluation of synergistic effect of Zerumbone with Cisplatin on anti-angiogenic potential in zebrafish model.

Dayalan Haripriya, Jegannathan Srimathi Devi, Arul Santhosh, Giridharan Bupesh, Mayur Mausoom Phukan, Jogeswar Panigrahi, Chitta Ranjan Deb, Manickam Mathyazhagan, Dharmalingam Kirubakaran, Konda Mani Saravanan and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dayalan HaripriyaDepartment of Biotechnology, Rajalakshmi Engineering College (Affiliated to Anna University), Thandalam, Chennai, 602105, Tamil Nadu, India. haripriya.d@rajalakshmi.edu.in.
Jegannathan Srimathi DeviDepartment of Biotechnology, Rajalakshmi Engineering College (Affiliated to Anna University), Thandalam, Chennai, 602105, Tamil Nadu, India.
Arul SanthoshDepartment of Biotechnology, Rajalakshmi Engineering College (Affiliated to Anna University), Thandalam, Chennai, 602105, Tamil Nadu, India.
Giridharan BupeshDepartment of Forestry, Nagaland University, Lumami, 798627, Nagaland, India. bupeshgiri@nagalanduniversity.ac.in.
Mayur Mausoom PhukanDepartment of Forestry, Nagaland University, Lumami, 798627, Nagaland, India.
Jogeswar PanigrahiDepartment of Biotechnology, Berhampur University, Berhampur, 761008, Odisha, India.
Chitta Ranjan DebDepartment of Botany, Nagaland University, Lumami, 798627, Nagaland, India.
Manickam MathyazhaganDepartment of Zoology, Nagaland University, Lumami, 798627, Nagaland, India.
Dharmalingam KirubakaranDepartment of Pharmacology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, 602105, Tamil Nadu, India.
Konda Mani SaravananDepartment of Biotechnology, Bharath Institute of Higher Education and Research, Chennai, 600073, Tamil Nadu, India.
Parasuraman PadmanabhanLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 636921, Singapore.
Domokos MatheIn Vivo Imaging Advanced Core Facility, Hungarian Center of Excellence for Molecular Medicine (HCEMM), 1094, Budapest, Hungary.
Govindaraju ArchunanDean-Research, Marudupandiyar College, Thanjavur, 613403, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiogenesis plays a critical role in cancer progression, highlighting the need for effective anti-angiogenic therapies. Zerumbone (ZER), a phytochemical compound, is known for its anti-angiogenic and anti-carcinogenic effects in various cancer cell lines. Cisplatin (CIS) is a widely used chemotherapeutic agent that effectively inhibits tumor growth. Combining CIS with anti-angiogenic agents like ZER may enhance the anticancer efficacy of CIS and improve treatment outcomes. This study aimed to evaluate the acute toxicity and anti-angiogenic effects of ZER, CIS, and the ZER + CIS combination in a zebrafish larval model. At higher concentrations, the ZER + CIS combination demonstrated only minimal toxicity. Both CIS and ZER exhibited significant anti-angiogenic activity, as indicated by the depletion of o-dianisidine-positive red blood cells in circulation compared to the control. The combination of ZER and CIS synergistically enhanced the down-regulation of VEGF-A (p < 0.001), VEGFR-2, NRP-1A, and NRP-2B, confirming the synergistic action of the two compounds. In conclusion, the combination of ZER and CIS exhibited superior anti-angiogenic effects compared to either treatment alone, suggesting a promising therapeutic strategy for cancer treatment.

Indexed as

Angiogenesis InhibitorsCisplatinNeovascularization, PathologicSesquiterpenesAnimalsAntineoplastic AgentsDisease Models, AnimalDrug SynergismVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2ZebrafishAngiogenesis InhibitorsAntineoplastic AgentsCisplatinSesquiterpenesVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2zerumboneAnti-angiogenesisCisplatinCombination therapyNatural productsZerumbone

Identifiers

PMID40500427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.